springworks merck - Search News

News

Merck KGaA to Buy US Drugmaker Springworks

Bloomberg on MSN · 1h

Merck KGaA’s $3.9 Billion Springworks Deal to Boost US Presence

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in the country.

Yahoo Finance · 5h

Merck KGaA strikes $3.9bn deal for SpringWorks

Merck KGaA (Merck) has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks Therapeutics. Under the deal, Merck will pay $47 per share in cash,

Reuters on MSN · 4h

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks

Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 billion to add rare cancer therapies ahead of expected revenue losses linked to expiring patents.

Fierce Pharma2h

Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

11h

Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.

Global Health Updates: From Mergers to Measles and Medicine

The latest health-related developments include Merck's acquisition talks with SpringWorks, disbandment of a US Justice ...

DPA International on MSN3d

German pharma giant Merck close to takeover of US cancer specialist

Germany's Merck is on the verge of a billion-euro takeover of US biopharmaceutical company Springworks Therapeutics, with the ...

3d

EQS-Adhoc: Merck KGaA: Merck confirms late-stage discussions with SpringWorks Therapeutics, Inc. on potential acquisition

EQS-Adhoc: Merck KGaA: Merck confirms late-stage discussions with SpringWorks Therapeutics, Inc. on potential acquisition ...

Health Headlines: From Measles Concerns to Pharma Developments

Gilead Sciences reports profits but mixed revenue; Merck is in talks to acquire SpringWorks for $3.5 billion; measles cases ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results